Tomohiro Higuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tomohiro Higuchi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ken Sugimoto
First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan
1 shared publication - Mihoko Yamade
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
1 shared publication - Moriya Iwaizumi
Department of Laboratory Medicine Hamamatsu University School of Medicine Shizuoka Japan
1 shared publication - Natsuki Ishida
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
1 shared publication - Satoru Takahashi
First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan
1 shared publication - Satoshi Osawa
Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
1 shared publication
Latest Publications
- Open Access
- 25 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3110
Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.
- 25 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3110
Open AccessExpectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.